News & Trends - Pharmaceuticals

Roche’s adjuvant treatment PBS listed in early breast cancer

Health Industry Hub | April 1, 2020 |
[Total: 2    Average: 5/5]

Effective 1st April 2020, Roche’s Kadcyla is listed on the Pharmaceutical Benefits Scheme (PBS), for the adjuvant treatment of patients with HER2-positive early breast cancer (eBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

In the adjuvant setting, Kadcyla was found to have reduced disease recurrence by 50% (HR=0.50, 95% CI 0.39-0.64; p<0.001) in patients with HER2-positive early breast cancer, who had residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.

Associate Professor Elisabeth Elder, specialist breast surgeon and head of research at the Westmead Breast Cancer Institute said “As a surgeon and a member of the multidisciplinary team, the shared goal is to provide the patient with optimal treatment options and ultimately maximise success in eliminating the disease. Neoadjuvant therapy is a key part of ensuring that patients are not losing further treatment options like adjuvant Kadcyla.”

HCP engagement during COVID-19. Health Industry Hub combines expertise in target audience insights, delivering digital health content and measuring engagement with 20+ years industry experience. Created by industry for industry. Contact us.

Australian guidelines recommend that treatment of early breast cancer be provided by a multidisciplinary team, consisting of at least a surgeon, medical oncologist, radiation oncologist, radiologist and nurse, to ensure optimal patient outcomes.

As surgeons are often the first point of contact for breast cancer patients along the treatment journey, they play an important role in identifying patients who would benefit from neoadjuvant therapy.

Breast surgeon and Vice President of BreastSurgANZ, Dr. Melanie Walker further highlighted the advantages of neoadjuvant treatment in helping to improve patient outcomes by offering additional treatment options in the adjuvant setting.

“Neoadjuvant therapy can act as an in vivo model of disease that is important prognostically for assessing tumour response to treatment and allowing adaptation in post-surgery treatment to maximise patient outcomes. It is no longer simply a tool for improving surgical outcomes but a crucial part of the optimal treatment pathway,” said Dr. Walker.

According to international guidelines, neoadjuvant treatment should be considered for all appropriate patients, especially those with HER2-positive and triple-negative breast cancer, as part of optimal treatment planning.

According to medical oncologist, Dr Richard de Boer, from St Vincent’s Private Hospital Melbourne, “The changing algorithm of treatment in early breast cancer means we can offer patients with HER2-positive breast cancer better treatment options that can reduce the risk of disease recurrence – which is a significant cause of anxiety for breast cancer patients.”

Register FREE and join 20,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

Breast cancer is the most common cancer affecting Australian women, with 1 in 7 women being diagnosed with breast cancer by the age of 85.8. In 2020, it is estimated that around 20,000 women and 170 men will be diagnosed with breast cancer.

HER2-positive cancer accounts for approximately 15-20% of breast cancer cases and is associated with a more aggressive form of the disease.

Roche Australia Managing Director Stuart Knight said “I congratulate the Federal Government on expediting the PBS listing of Kadcyla. Roche has a long heritage of innovation in breast cancer cancer, and I’m delighted that eligible patients now have an additional option for the adjuvant treatment of HER2-positive early breast cancer.”

You may also like MSD, Novartis and more unite alongside Gates Foundation in the flight against COVID-19


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Varian's AI machine personalises cancer therapy and halves treatment time

Varian’s AI machine personalises cancer therapy and halves treatment time

Health Industry Hub | June 3, 2020 |

MedTech News: A Sydney patient is the first Australian in the Southern Hemisphere to receive revolutionary new personalised cancer therapy […]

More


News & Trends - Pharmaceuticals

Pharma News - ASCO highlights - Janssen, Takeda, AZ, Genentech, MSD, BMS and Noxopharm

ASCO highlights – Janssen, Takeda, AZ, Genentech, MSD, BMS and Noxopharm

Health Industry Hub | June 3, 2020 |

Pharma News: The American Society of Clinical Oncology (ASCO) 2020 meeting was held virtually this year due to the COVID-19 […]

More


News & Trends - Medical Technology

MedTech News - Siemens COVID-19 antibody test to be delivered worldwide

Siemens COVID-19 antibody test to be delivered worldwide

Health Industry Hub | June 3, 2020 |

MedTech News: Siemens Healthineers is now shipping worldwide its laboratory-based total antibody test to detect the presence of SARS-CoV-2 IgM and […]

More


Leadership & Management

Leadership Management Qualities - Overwhelming call for a better normal

Overwhelming call for a ‘better normal’

Health Industry Hub | June 3, 2020 |

People are rejecting corporate and government thinking on the ‘return to normal’ and want to keep the work-life-changes they have […]

More